GuidelineJournal of gastroenterology and hepatology2009
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.
Guideline in Journal of gastroenterology and hepatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 241 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)
Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication
The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies
A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection
A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment
Who cites it
241 citing papers in PubMed, 14 syntheses or guidelines pooled it, 551 citations in OpenAlex.
- Functional dyspepsia overlapping with other functional gastrointestinal disorders: a bibliometric and visualization analysis.Frontiers in medicine · 2026Pooled it
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Pooled it
- Concomitant or Sequential Therapy as the First-line Therapy for Eradication ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2018Pooled it
- Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.PloS one · 2018Pooled it
- The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis.Medicine · 2017Pooled it
- Pooled it
- Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.World journal of gastroenterology · 2016Pooled it
- Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?World journal of gastroenterology · 2015Pooled it
- Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?Journal of Korean medical science · 2014Pooled it
- Pooled it
- Optimum duration of regimens for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2013Pooled it
- Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial.Asian Pacific journal of cancer prevention : APJCP · 2020Trial
- Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Trial
- Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Trial
- Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018Trial
- Trial
- A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.Antimicrobial agents and chemotherapy · 2017Trial
181 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 15 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Asia-Pacific Consensus Conference was convened to review and synthesize the most current information on Helicobacter pylori management so as to update the previously published regional guidelines. The group recognized that in addition to long-established indications, such as peptic ulcer disease, early mucosa-associated lymphoid tissue (MALT) type lymphoma and family history of gastric cancer, H. pylori eradication was also indicated for H. pylori infected patients with functional dyspepsia, in those receiving long-term maintenance proton pump inhibitor (PPI) for gastroesophageal reflux disease, and in cases of unexplained iron deficiency anemia or idiopathic thrombocytopenic purpura. In addition, a population 'test and treat' strategy for H. pylori infection in communities with high incidence of gastric cancer was considered to be an effective strategy for gastric cancer prevention. It was recommended that H. pylori infection should be tested for and eradicated prior to long-term aspirin or non-steroidal anti-inflammatory drug therapy in patients at high risk for ulcers and ulcer-related complications. In Asia, the currently recommended first-line therapy for H. pylori infection is PPI-based triple therapy with amoxicillin/metronidazole and clarithromycin for 7 days, while bismuth-based quadruple therapy is an effective alternative. There appears to be an increasing rate of resistance to clarithromycin and metronidazole in parts of Asia, leading to reduced efficacy of PPI-based triple therapy. There are insufficient data to recommend sequential therapy as an alternative first-line therapy in Asia. Salvage therapies that can be used include: (i) standard triple therapy that has not been previously used; (ii) bismuth-based quadruple therapy; (iii) levofloxacin-based triple therapy; and (iv) rifabutin-based triple therapy. Both CYP2C19 genetic polymorphisms and cigarette smoking can influence future H. pylori eradication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.